[1] CHIENG N,RADES T,AALTONEN J. An overview of recent studies on the analysis of pharmaceutical polymorphs[J]. J Pharm Biomed Anal,2011,55(4):618-644.
[2]PUROHIT R,VENUGOPALAN P. Polymorphism:an overview[J]. Resonance,2009,14(9):882-893.
[3]VIPPAGUNTA S R,BRITTAIN H G,GRANT D J W. Crystalline solids[J]. Adv Drug Deliv Rev,2001,48(1):3-26.
[4]KARPINSKI P H. Polymorphism of active pharmaceutical ingredients[J]. Chem Eng Technol,2006,29(2):233-237.
[5]RAW A. Pharmaceutical solid polymorphism in drug development and regulation[J]. Adv Drug Deliv Rev,2004,56(3):235-236.
[6]LLINAS A,GOODMAN J M. Polymorph control:past,present and future[J]. Drug Discov Today,2008,13(5/6):198-210.
[7]RAW A S,FURNESS,M S,GILL D S,et al. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications(ANDAs)[J]. Adv Drug Deliv Rev,2004,56(3):397-414.
[8]NEWMAN A W,BYRN S R. Solid-state analysis of the active pharmaceutical ingredient in drug products[J]. Drug Discov Today,2003,8(19):898-905.
[9]STEPHENSON G A,FORBES R A,REUTZEL E S M. Characterization of the solid state quantitative issues[J]. Adv Drug Deliv Rev,2001,48(1):67-90.
[10]NEMET Z,KIS G C,POKOL G. Quantitative determination of famotidine polymorphs:X-ray powder diffractometric and Raman spectrometric study[J]. J Pharm Biomed Anal,2009,49(2):338-346.
[11]LI Y,CHOW P S,TAN R B. Quantification of polymorphic impurity in an enantiotropic polymorph system using differential scanning calorimetry,X-ray powder diffraction and Raman spectroscopy[J]. Int J Pharm,2011,415(1/2):110-118.
[12]TAKEHIRA R,MOMOSE Y,YAMAMURA S. Quantitative analysis of crystalline pharmaceuticals in tablets by pattern-fitting procedure using X-ray diffraction pattern[J]. Int J Pharm,2010,398(1/2):33-38.
[13]CROKER D M,HENNIGAN M C,MAHER A,et al. A comparative study of the use of powder X-ray diffraction,Raman and near infrared spectroscopy for quantification of binary polymorphic mixtures of piracetam[J]. J Pharm Biomed Anal,2012,63(7):80-86.
[14]PETKUNE S,BOBROVS R,ACTINS A. Determination of trace amounts of beta tegafur in commercial alpha tegafur by powder X-ray diffractometric analysis[J]. J Pharm Pharmacol,2011,63(9):1 136-1 140.
[15]ALAM S,PATEL S,BANSAL A K. Effect of sample preparation method on quantification of polymorphs using PXRD,Pharm[J]. Dev Technol,2010,15(5):452-459.
[16]ATICI E B,KARLIGA B. Quantitative determination of two polymorphic forms of imatinib mesylate in a drug substance and tablet formulation by X-ray powder diffraction,differential scanning calorimetry and attenuated total reflectance Fourier transform infrared spectroscopy[J]. J Pharm Biomed Anal,2015,114:330-340.
[17]VARASTEH M,DENG Z,HWANG H,et al. Quantitative determination of polymorphic impurity by X-ray powder diffractometry in an OROS formulation[J]. Int J Pharm,2009,366(1/2):74-81.
[18]ROBERTS S N C,WILLIAMS A C,GRIMSEY I M,et al. Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry—exploring preferred orientation effects[J]. J Pharm Biomed Anal,2002,28(6):1 149-1 159.
[19]BEZZON V D,ANTONIO S G,PAIVA S C O. Limits of visual detection for finasteride polymorphs in prepared binary mixtures:analysis by X-ray powder diffraction[J]. J Pharm Sci,2014,103(11):3 567-3 575.
[20]BRUNI G,BERBENNI V,MILANESE C,et al. Determination of the nateglinide polymorphic purity through DSC[J]. J Pharm Biomed Anal,2011,54(5):1 196-1 199.
[21]LIN S Y. An overview of famotidine polymorphs:solid-state characteristics,thermodynamics,polymorphic transformation and quality control[J]. Pharm Res,2014,31(7):1 619-1 631.
[22]CLAS S D,DALTON C R,HANCOCK B C. Differential scanning calorimetry:applications in drug development[J]. Pharm Sci Technol To,1999,2(8):311-320.
[23]RIEKES M K,PEREIRA R N,RAUBER G S,et al. Polymorphism in nimodipine raw materials:development and validation of a quantitative method through differential scanning calorimetry[J]. J Pharm Biomed Anal,2012,70(11):188-193.
[24]TONG H H Y,SHEKUNOV B Y,YORK P,et al. Thermal analysis of trace levels of polymorphic impurity in salmeterol xinafoate samples[J]. Pharma research,2003,20(20):1 423-1 429.
[25]VIRTANEN T,MAUNU S L. Quantitation of a polymorphic mixture of an active pharmaceutical ingredient with solid state(13)C CPMAS NMR spectroscopy[J]. Int J Pharm,2010,394(1/2):18-25.
[26]VICKERYA R D,NEMETH G A,MAURIN M B. Solid-state carbon NMR characterization of the polymorphs of roxifiban[J]. J Pharm Biomed Anal,2002,30(1):125-129.
[27]PAN D,CRULL G,YIN S,et al. Low level drug product API form analysis-Avalide tablet NIR quantitative method development and robustness challenges[J]. J Pharm Biomed Anal,2014,89(4):268-275.
[28]PIQUERAS S,DUPONCHEL L,TAULER R,et al. Monitoring polymorphic transformations by using in situ Raman hyperspectral imaging and image multiset analysis[J]. Anal Chim Acta,2014(819):15-25.
[29]LI B,CALVET A,CASAMAYOU B Y,et al. Low-content quantification in powders using Raman spectroscopy:a facile chemometric approach to sub 0.1% limits of detection[J]. Anal Chem,2015,87(6):3 419-3 428.
[30]HU Y,ERXLEBEN A,RYDER A G,et al. Quantitative analysis of sulfathiazole polymorphs in ternary mixtures by attenuated total reflectance infrared,near-infrared and Raman spectroscopy[J]. J Pharm Biomed Anal,2010,53(3):412-420.
[31]BURLEY J C,AINA A,MATOUSEK P,et al. Quantification of pharmaceuticals via transmission Raman spectroscopy:data sub-selection[J]. Analyst,2014,139(1):74-78.
[32]BUGAY D E. Characterization of the solid state quantitative issues[J]. Adv Drug Deliv Rev,2001,48(1):43-65.
[33]ALEXANDER L,KLUG H P. Basic aspects of X-ray absorption in quantitative diffraction analysis of powder mixtures[J]. Anal Chem,1948,20(10):886-889.
[34]SMITH D K,JR G G J,SCHEIBLE A,et al. Quantitative X-ray powder diffraction method using the full diffraction pattern[J]. Powder Diffr,1987,2(2):73-77.
[35]MOORE M D,COGDILL R P,WILDFONG P L D. Evaluation of chemometric algorithms in quantitative X-ray powder diffraction(XRPD)of intact multi-component consolidated samples[J]. J Pharm Biomed Anal,2009,49(3):619-626.
[36]TORAYA H,TSUSAKA S. Quantitative phase analysis using the whole-powder-pattern decomposition method.Ⅰ. solution from knowledge of chemical compositions[J]. J Appl Cryst,1995,28(4):392-399.
[37]UVAROV V,POPOV I. Development and metrological characterization of quantitative X-ray diffraction phase analysis for the mixtures of clopidogrel bisulphate polymorphs[J]. J Pharm Biomed Anal,2008,46(4):676-682.
[38]ANTONIO S G,BENINI F R,FERREIRA F F P,et al. Quantitative phase analyses through the rietveld method with X-ray powder diffraction data of heat-treated carbamazepine form III[J]. J Pharma Sci,2011,100(7):2 658-2 664.
[39]SCARLETT N V Y,MADSEN I C. Quantification of phases with partial or no known crystal structures[J]. Powder Diffr,2006,21(4):278-284.
[40]CHIENG N,REHDER S,SAVILLE D,et al. Quantitative solid-state analysis of three solid forms of ranitidine hydrochloride in ternary mixtures using Raman spectroscopy and X-ray powder diffraction[J]. J Pharm Biomed Anal,2009,49(1):18-25.
[41]ANDREA H,MARJA S,THOMAS R,et al. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy[J]. Eur J Pharm Sci,2007,32(3):182-192.
[42]PRATIWI D,FAWCETT J P,GORDON K C,et al. Quantitative analysis of polymorphic mixtures of ranitidine hydrochloride by Raman spectroscopy and principal components analysis[J]. Eur J Pharm Biopharm,2002,54(3):337-341.
[43]CALIANDRO R,DI PROFIO G,NICOLOTTI O. Multivariate analysis of quaternary carbamazepine-saccharin mixtures by X-ray diffraction and infrared spectroscopy[J]. J Pharm Biomed Anal,2013,78-79(9):269-279.
[44]STRACHAN C J,PRATIWI D,GORDON K C,et al. Quantitative analysis of polymorphic mixtures of carbamazepine by Raman spectroscopy and principal components analysis[J]. J Raman Spectrosc,2004,35(5):347-352.
[45]VITEZ I M. Utilization of DSC for Pharmaceutical crystal form quantitation[J]. J Therm Anal Calorim,2004,78(1):33-45.
[46]LIEDER T R. FDA approves nateglinide for treatment of type 2 diabetes[J]. Am J health Syst Pharm,2001,58(4):285-288.
[47]LI G,XU Q W,LI R,et al. Polymorphism and Solubility of Nateglinide[J]. Acta Chim Sinica,2007,65(24):2 817-2 820.
[48]LI G,XU Q W,MO X Y,et al. Study on stability of nateglinide polymorphism[J]. Acta Chim Sinica,2003,61(2):291-294.
[49]SUMIKAWA M,KOGUCHI Y,OHGANE T,et al. Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them:US,5488150[P]. 2004-01-30.
[50]LI G,CHEN J Y,Lü G L,et al. Determination of the nateglinide polymorphism structure and the drug effect[J]. Acta Pharm Sinica,2005,40(10):958-960.
[51]Center for Drug Evaluation and Research,Center of Biologics Evaluation and Research,Food and Drug Administration. FDA Guidance for industry:Q2B validation of analytical procedures[S]. US:ICH,1996.